| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2007: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
Considering the notion, prevailing in western countries, that the pharmaceutical should not be reimbursed by health insurance unless its Incremental Cost-effectiveness Ratio (ICER) is less than some pre-decided value, we tried to find the pre-decided value suitable to Japanese system based on the prices of 73 new products in Japan. ICER varied widely from 1200000 yen to 19000000 yen. This indicates that the current rule for calculating pharmaceuticals' price dose not necessarily reflect cost-effectiveness of new pharmaceutical. Reverse correlation was found between ICER for a disease and medical satisfaction. It suggests that ICERs for diseases classified by medical satisfaction can be used as pre-decided values under current price calculating system.
|
